CLEVELAND—Ganeden Biotech announced that Ganeden BC30, a highly stable probiotic ingredient, received numerous international regulatory approvals and is now being shipped to six continents. The global market of probiotic ingredients, supplements and foods is expected to reach USD $36.7 billion in 2018, according to Wellesley, Massachusetts- based technology markets research firm BCC Research.
"The international probiotic market is growing at a breakneck pace, and the interest in GanedenBC30 is astounding," said Mike Bush, senior vice president at Ganeden Biotech. "Achieving a Global footprint for GanedenBC30 has been an ongoing goal for Ganeden Biotech that could only be achieved by a significant investment in international regulatory compliance and patent prosecution, working with international distributors and continuing to publish studies in peer reviewed journals that support claims for safety and efficacy."
Ganeden Biotech has received regulatory approvals for GanedenBC30 in more than 60 countries throughout North America, Asia, Europe, South America, Africa and Oceania; which has resulted in six international product launches in the first quarter of 2014. By the end of the year, Ganeden expects to receive approvals in six additional countries with many more to come in 2015.